NCT04768608View on ClinicalTrials.gov

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

May 30, 2023

Conditions

Castrate-Resistant Prostate Cancer

Interventions

DRUG

PD1-PSMA-CART cells

PD1-PSMA-CART cells will be given IV at split doses

Trial Locations (1)

Unknown

The First Affiliated Hospital, Zhejiang University, Hangzhou

Sponsors

Collaborators (1)

Bioray Laboratories

All Listed Sponsors

collaborator

Bioray Laboratories

INDUSTRY

lead

Zhejiang University

OTHER

NCT04768608 - PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter